SEC Form 4 · accession 0000903423-15-000581
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
GLAXOSMITHKLINE PLC
10% Owner
Period of report
Oct 7, 2015
Accepted (ET)
Oct 7, 2015 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Oct 7, 2015 | P | 44,574 | $607,543.62 | A | 8,343,792 | I | By Corporation |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Ordinary shares purchased pursuant to the right of Glaxo Group Limited ("GGL"), an indirect wholly owned subsidiary of the Reporting Person, under Section 2.1(d)(ii) of the Governance Agreement by and among Theravance Biopharma, Inc. (the "Issuer") and GGL, dated as of March 3, 2014. Pursuant to Section 2.1(d)(ii), GGL has the right to purchase from the Issuer, on a quarterly basis, sufficient ordinary shares to maintain its ownership percentage in the Issuer taking into account the preceding quarter's option exercise and equity vesting activity.
- F2Ordinary Shares are held of record by GGL, an indirect wholly owned subsidiary of the Reporting Person.